Pilar Vidueira

Dr. Ferrer embarked on his distinguished career by obtaining a DVM degree in 1981, followed by a PhD in 1985, both from the University of Zaragoza, Spain. His pursuit of excellence continued as he earned a Master’s degree in Animal Pathology in 1983 from the Veterinary School of Hannover, Germany. In 1994, he reached a significant milestone by becoming a Board-Certified Dermatologist through the European College of Veterinary Dermatology. His tenure as a lecturer at the Cummings School of Veterinary Medicine at Tufts University has been marked by widespread recognition and respect for his academic contributions.

Dr. Ferrer’s tenure at the Universitat Autònoma de Barcelona’s Veterinary School since 1985 has been marked by his impactful contributions in teaching Pathology and Dermatology. His time at this renowned university is not only noted for his educational role but also for his leadership. He was the Dean of the Veterinary School from 1992 through 1998. Following this, he assumed the role of Vice-rector for Research from 1998 to 2002 and then progressed to the position of Rector of the University, a role he held from 2002 until 2009.

Dr. Ferrer’s research interests encompass a wide range of dermatological conditions, with a significant focus on cutaneous infections like canine leishmaniosis. His work extends to understanding canine atopic dermatitis and the genetic underpinnings of skin diseases. These contributions have not only advanced veterinary dermatology but also offered practical solutions for everyday clinical challenges​​​​.

Dr. Ferrer’s upcoming lecture at LeishVet ALIVE 2, titled “The conundrum of clinical relapses in canine leishmaniosis,” promises to be a highlight of the event. This lecture is poised to shed light on the complexities and challenges in managing this prevalent disease, offering invaluable insights for both practitioners and researchers​​.

Attending Dr. Ferrer’s lecture is an opportunity to glean knowledge from his vast experience and groundbreaking research. His perspective on canine leishmaniosis is expected to be both enlightening and transformative, offering new approaches and understandings that can be applied in clinical and research settings.

LeishVet ALIVE 2, 2024 is more than a conference; it’s a gateway to the forefront of veterinary medicine, particularly in the realm of Leishmaniasis. Dr. Ferrer’s lecture is a must-attend for anyone seeking to deepen their understanding and enhance their practice in this field.

Don’t let this opportunity pass you by. Register now for LeishVet ALIVE 2 and join us, either in person in Nice or online, to experience the wealth of knowledge and innovation that Dr. Lluis Ferrer and other experts bring to the table. Register Here

Welcome to the life and work of Dr. Jorge Alvar, a renowned figure in the world of medical research, specifically in the battle against Leishmaniasis. Dr. Alvar’s upcoming keynote lecture at ALIVE 2024, set in the picturesque city of Nice from April 18-20, 2024, is not just an event – it’s an insightful rendezvous with one of the most distinguished minds in tropical medicine.

His extensive career, from his early days at the Institute of Health Carlos III to his impactful role at the Drugs for Neglected Disease initiative (DNDi) in Geneva, has been marked by relentless dedication to combating neglected tropical diseases. With over 40 years of experience, his extensive list of publications has garnered more than 26,000 citations, and he boasts an h-index of 69. Additionally, he holds membership in the prestigious Royal Academy of Medicine of Spain.

In the realm of tropical medicine, few names resonate as profoundly as that of Dr. Jorge Alvar. His journey, originating from the prestigious halls of the University of Madrid, where he earned his medical degree and PhD, has been nothing short of extraordinary. Dr. Alvar’s passion for combating parasitic diseases led him to further his expertise with a master’s degree in Malaria & Environmental Health from Carabobo University, Venezuela, and a diploma in Tropical Medicine & Parasitology from Hamburg, Germany.

His early career saw him immersed in the world of parasitology and public health, working diligently at the Institute of Health Carlos III. Here, Dr. Alvar not only honed his skills as a scientist but also emerged as a leader, eventually heading the Department of Parasitology. His tenure was marked by significant strides in confronting parasitic epidemics and establishing a public health laboratory in Equatorial Guinea, a testament to his dedication to improving global health.

The turn of the millennium brought new challenges and opportunities for Dr. Alvar. In 2000, he assumed the role of Director of the National Centre of Tropical Medicine. But perhaps his most notable contribution to global health came with his role in the Leishmaniasis World Program at the World Health Organization (WHO). There, he spearheaded strategic plans and control programs in East Africa and South Asia, tackling the disease head-on.

Dr. Alvar’s expertise and impact extended beyond organizational boundaries when he joined the DNDi in Geneva. As the head, and later Senior Adviser, of the drug development program for Leishmaniasis, he played a pivotal role in advancing research and treatment for this neglected disease. His efforts have not gone unnoticed; his research in epidemiology and diagnosis of Leishmaniasis has earned him numerous awards and recognition, including an impressive citation record and a high h-index factor.

Throughout his career, Dr. Alvar has been a symbol of optimism and innovation in the fight against Leishmaniasis. His work has spanned continents, involving him in over 30 research projects or clinical trials and bringing his expertise to communities in dire need. As a member of the Royal Academy of Medicine of Spain, his contributions to medical science and public health continue to inspire and drive progress in the field.

As we look forward to his keynote lecture at ALIVE 2024, it’s clear that Dr. Alvar’s journey is far more than a career; it’s a lifelong mission to eradicate one of the world’s most debilitating diseases. His story is not just one of scientific achievement but of profound human impact, a narrative that continues to unfold and inspire those dedicated to the field of tropical medicine and global health​​.

In the landscape of global health, the Drugs for Neglected Disease initiative (DNDi) stands as a towering testament to innovative and humanitarian approaches to medicine. Dr. Jorge Alvar’s involvement with DNDi marks a crucial chapter in his illustrious career, reflecting a profound commitment to addressing diseases often overlooked by mainstream medical research.

DNDi emerged from a noble vision: to bring much-needed attention and resources to the fight against neglected tropical diseases (NTDs). It was founded in 2003, following a decision by Médecins Sans Frontières to allocate part of their Nobel Peace Prize funds to this cause. This initiative signified a paradigm shift in how the medical community approached NTDs, including Leishmaniasis, which affects over a billion people, predominantly in impoverished communities.

Under Dr. Alvar’s guidance, DNDi focused on developing treatments that are not only effective but also accessible and easy to administer. This approach is crucial in areas where medical resources are scarce and the burden of disease is high. The initiative’s work, recognized through prestigious awards like the Princesa de Asturias Award for International Cooperation, underscores the impact of collaborative, non-profit research in changing the global health landscape.

Dr. Alvar’s role in DNDi was instrumental in steering the organization towards groundbreaking research and development. His leadership helped bridge the gap between scientific innovation and practical, life-saving applications in the field. The initiative’s success is a testament to Dr. Alvar’s vision of a world where the scourge of NTDs is a thing of the past, a vision that he continues to pursue with relentless passion and dedication.

Over the past decade, under the stewardship of Dr. Jorge Alvar and organizations like DNDi, there has been significant progress in combating Neglected Tropical Diseases (NTDs). This journey, however, is marked by both remarkable achievements and ongoing challenges.

The concerted international effort against NTDs has resulted in substantial strides forward. For instance, the past ten years have seen 500 million people no longer requiring NTD control programs. Diseases like lymphatic filariasis and trachoma have been eliminated as public health problems in several countries. The success stories extend to leishmaniasis in Southeast Asia and the near-eradication of Guinea worm disease.

However, these triumphs exist alongside persistent challenges. NTDs, closely linked to poverty, continue to demand substantial investment in research and healthcare infrastructure strengthening. Dr. Alvar stresses the critical need for continued focus on these diseases, underscoring their intimate connection to impoverished conditions and remote regions. The fight against NTDs is not just a medical challenge but also a socio-economic one, requiring holistic approaches and sustained efforts.

Moreover, the emergence of new challenges such as COVID-19 has disrupted control programs and funding, highlighting the fragility of progress and the need for resilience in public health initiatives. Dr. Alvar’s insights into these complex dynamics will be pivotal in his upcoming lecture at ALIVE 2024, offering a comprehensive view of the past achievements and future directions in the battle against NTDs​​​​.

In the intricate tapestry of global health, the impact of broader factors like climate change and population dynamics becomes increasingly evident, a theme that Dr. Jorge Alvar has often highlighted in his work. The phenomenon known as the “Great Acceleration,” driven by population growth and its associated activities, disproportionately affects developing countries. These countries, already burdened with neglected tropical diseases (NTDs), now face additional challenges posed by climate change.

The rise in global temperatures, now seemingly unstoppable, has immediate health implications. It not only exacerbates malnutrition and increases the incidence of violent episodes but also influences the spread of NTDs. Diseases once confined to tropical and subtropical zones are now encroaching upon new areas, including temperate regions. A stark example is the Aedes albopictus mosquito, the carrier of diseases like chikungunya and dengue, which has expanded its habitat to southern Europe.

Furthermore, environmental degradation is forcing wildlife, potential reservoirs of various pathogens, closer to human habitats. This proximity increases the risk of new zoonoses, diseases transmitted from animals to humans, a significant concern in tropical regions where 60% of emerging diseases are zoonotic in origin.

Dr. Alvar’s insights into these global dynamics underline the interconnected nature of NTDs, environmental change, and public health. His perspective sheds light on the necessity of a multidimensional approach to health, one that integrates environmental and social factors into the fight against diseases like Leishmaniasis​​.

In the realm of medical research and treatment, innovation is the key to progress. This is particularly true in the work of Dr. Jorge Alvar, whose contributions to Leishmaniasis treatment have been groundbreaking. His approach has not only improved existing treatments but has also introduced new, more effective methods.

Under Dr. Alvar’s guidance, the treatment of Leishmaniasis, especially in patients co-infected with HIV, has seen remarkable improvements. Traditional treatment methods, once only moderately effective, have evolved into more efficient regimes, dramatically increasing the success rate. These advancements are a testament to Dr. Alvar’s deep understanding of the disease and his commitment to finding more effective solutions.

One of the hallmarks of his approach is the development of treatments that are easier to administer. The move from injectables to oral medications, for example, represents a significant step forward in patient care. This shift not only reduces the risks associated with injections but also makes treatment more accessible, especially in remote areas where medical resources are scarce.

Dr. Alvar’s innovative strategies in tackling Leishmaniasis are expected to be a major highlight of his keynote speech at ALIVE 2024. His work exemplifies the importance of continuous research and adaptation in the field of tropical medicine and offers hope for better treatment methods for those affected by this disease​​.

As we conclude this exploration of Dr. Jorge Alvar’s significant contributions to the field of tropical medicine, particularly in combating Leishmaniasis, it becomes evident that his journey is a beacon of hope and a source of inspiration. His accomplishments, from groundbreaking research to innovative treatment methods, have not only advanced medical science but also transformed the lives of countless individuals affected by neglected tropical diseases.

Looking forward to his keynote lecture at ALIVE 2024, it’s clear that Dr. Alvar’s insights will be invaluable to both veterinarians and researchers. His unique perspective, blending scientific expertise with a deep understanding of the social and environmental factors affecting health, makes his address a must-attend event for professionals in the field.

As we draw inspiration from Dr. Jorge Alvar’s journey and achievements, we invite you to join us at ALIVE 2024. This conference presents a unique opportunity to engage with leading minds in the field of Leishmaniosis research and treatment. Whether you are a veterinarian eager to learn about the latest developments in combating this disease, or a researcher seeking insights into innovative treatment methodologies, ALIVE 2024 is the place to be.

Register now to be part of this enlightening experience in Nice. Engage with experts, share knowledge, and contribute to the global effort in tackling Leishmaniosis and other neglected tropical diseases. Let’s come together to make a difference in the world of tropical medicine.

The LeishVet Scientific Committee is gearing up to host this event in a hybrid format, ensuring that participants can engage both in-person and view virtually. This congress promises to bring together the crème de la crème of experts specializing in animal leishmaniosis. It’s not just a gathering of experts, but also an opportunity to meet all the LeishVet members.

The second ALIVE congress, also known as the Animal Leishmaniosis International Veterinary Event, has an enriching Scientific Program lined up. Just like its inaugural edition, the program will be bifurcated into two main streams:

• Research Stream: Dive deep into the latest findings and advancements in the field of animal leishmaniosis
• Clinical Stream: Gain insights into the clinical diagnosis and treatment methodologies for this significant zoonotic disease

In addition to these streams, attendees will have the exclusive chance to participate in round table discussions alongside esteemed speakers and LeishVet members. These discussions will revolve around real clinical cases, epidemiology, diagnosis, treatment, and preventive measures related to animal leishmaniosis.

• Kick-off Evening: Attendees are welcomed with a cocktail at the Radisson Blu’s Rooftop, setting the ambiance for the upcoming sessions.
• Both days commence with an Informal Get Together for young scientists and clinicians, fostering collaboration and networking.
• Notable sessions include discussions on:
  • ophthalmic challenges in animal leishmaniosis
  • Leishmania donovani in India
  • other Leishmania species infecting dogs
  • the impact of Phlebotomine sand flies on health.
  • when clinicians should suspect feline leishmaniosis
  • clinical relapses in canine leishmaniosis
  • unexpected lessons of leishmaniosis
  • the role of extracellular vesicles in canine leishmaniosis
• Keynote speakers like Carla Maia,  Christopher Fernandez-Prada, Christine Petersen, Filipe Dantas-Torres, Marta Leiva, Alessandra Fondati, Manolis Saridomichelakis and Lluís Ferrer share their expertise on various facets of leishmaniosis.
• Interspersed with these sessions are Oral Communications, Round Tables, and Poster Sessions, offering a platform for diverse voices in the field.

The highlight of Friday evening is a Gala Dinner, while the congress concludes on Saturday with a formal Closing Ceremony.

The congress is set to be hosted at the luxurious Hotel Radisson Blu, located on the iconic Promenade des Anglais in Nice. The hotel is conveniently situated just 4 km away from the Nice Côte d’Azur International Airport and a mere 5 km from the city’s bustling center. While most of the congress activities will be held within the hotel premises, attendees can look forward to a special Gala Dinner with complimentary transportation which will be arranged for this dinner event.

For those who might not be able to attend in person, don’t fret! The entire event will be streamed online, ensuring that no one misses out on this unique learning opportunity.

For more detailed information about the ALIVE congress, including registration details and the full program, visit the official website at www.leishvet-alive.com. You can also follow updates on their social media channels. Should you have any questions or require further information, feel free to reach out to the organizers at social@leishvet-alive.com.